AVBP · CIK 0001868279
What ArriVent BioPharma, Inc. told the SEC could break it.
ArriVent's disclosures concentrate on a China-centered footprint for a company whose near-term prospects ride on one lead candidate, firmonertinib. It relies on a small number of China-based contract manufacturers (Raybow, WuXi STA, WuXi XDC) for the drug substance and product of firmonertinib and ARR-217, and several of its pivotal trials are run outside the U.S., including in China — data the FDA may not fully accept, which would delay development. That offshore positioning collides with trade policy: a September 2025 proposed 100% tariff on branded or patented drugs (unless U.S. manufacturing expands), tariffs on raw materials, possible BIOSECURE-type restrictions, and IRA Medicare price negotiation all threaten its cost structure and future economics.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- proposed 100% tariff on branded/patented drugs; tariffs on raw materials; IRA price negotiationhigh
A September 2025 announced 100% tariff on brand-name/patented drugs (unless manufacturing is expanded in the U.S.), tariffs still applying to raw materials, and IRA Medicare drug-price negotiation collectively threaten ArriVent's cost structure and future firmonertinib economics given its offshore manufacturing.
“On September 25, 2025, the current U.S. administration announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S., and may impose more restrictions on goods.”
SEC filing →As of 2026
Geographic concentration
- firmonertinib & ARR-217 drug substance/product made only by China-based CMsmedium
ArriVent relies on a small number of China-based contract manufacturers (Raybow, WuXi STA, WuXi XDC) for firmonertinib and ARR-217 drug substance and product; both CMs being in China exposes it to supply disruption, a U.S.-China trade war, NDAA FY2026 (BIOSECURE-type) restrictions and regulatory-framework changes.
“Both third-party contract manufacturers are located in China, and we expect to continue to use such third-party manufacturers for such firmonertinib drug substance and drug product supplies.”
Other disclosures
- lead-asset concentration in firmonertinib; foreign (China) trial-data acceptance riskmedium
ArriVent's near-term prospects depend heavily on its lead candidate firmonertinib, several of whose pivotal trials (and an ARR-217 trial) are conducted outside the U.S. including in China; the FDA may not accept that foreign data, delaying development and harming the business.
“Several of the ongoing clinical trials for our lead product candidate, firmonertinib, and an ongoing trial for ARR-217, are being conducted outside the United States, including in China. However, the FDA and foreign regulatory equivalents may not accept data from such trials, or may expect proportionately more data from subjects in the United States, in which case our development plans will be delayed, which could materially harm our bu”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Allist Pharmaceuticals
“In consideration of the licenses and rights granted to us under the Allist License Agreement, we granted to Allist a total of 1,276,250 shares of common stock for a purchase price of $0.0001 per share pursuant to that certain Subscription Agreement executed concurrently with the Allist License Agreement.”
Cited →Raybow Pharmaceutical
“Currently, we rely on and have agreements with two third-party contract manufacturers, Raybow and WuXi STA, to supply the drug substance for firmonertinib for use in ongoing and planned clinical trials.”
Cited →WuXi XDC
“We expect to rely on manufacturers in China for ARR-217 drug substance and drug product for use in clinical studies and also expect to rely on WuXi XDC”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch